SEK 1.54
(1.18%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 238.37 Million SEK | -38.14% |
2022 | 385.32 Million SEK | -12.3% |
2021 | 439.37 Million SEK | -53.59% |
2020 | 946.75 Million SEK | -4.7% |
2019 | 993.48 Million SEK | 123.49% |
2018 | 444.53 Million SEK | -7.36% |
2017 | 479.82 Million SEK | 762.48% |
2016 | 55.63 Million SEK | 1163.8% |
2015 | 4.4 Million SEK | -66.46% |
2014 | 13.12 Million SEK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 452.92 Million SEK | 126.81% |
2024 Q1 | 199.69 Million SEK | -16.23% |
2023 Q2 | 355.99 Million SEK | 12.34% |
2023 Q3 | 294.97 Million SEK | -17.14% |
2023 Q4 | 238.37 Million SEK | -19.19% |
2023 Q1 | 316.88 Million SEK | -17.76% |
2023 FY | 238.37 Million SEK | -38.14% |
2022 Q3 | 475.99 Million SEK | 219.17% |
2022 Q1 | 261.06 Million SEK | -40.58% |
2022 Q2 | 149.13 Million SEK | -42.87% |
2022 FY | 385.32 Million SEK | -12.3% |
2022 Q4 | 385.32 Million SEK | -19.05% |
2021 FY | 439.37 Million SEK | -53.59% |
2021 Q4 | 439.37 Million SEK | -46.9% |
2021 Q3 | 827.45 Million SEK | -49.54% |
2021 Q2 | 1.63 Billion SEK | 133.64% |
2021 Q1 | 701.86 Million SEK | -25.87% |
2020 Q2 | 1.04 Billion SEK | 56.44% |
2020 Q4 | 946.75 Million SEK | -28.37% |
2020 Q3 | 1.32 Billion SEK | 26.84% |
2020 Q1 | 666.1 Million SEK | -32.95% |
2020 FY | 946.75 Million SEK | -4.7% |
2019 Q1 | 841.33 Million SEK | 89.26% |
2019 Q3 | 1.14 Billion SEK | 62.52% |
2019 Q4 | 993.48 Million SEK | -13.17% |
2019 FY | 993.48 Million SEK | 123.49% |
2019 Q2 | 703.98 Million SEK | -16.33% |
2018 Q1 | 739.04 Million SEK | 54.02% |
2018 Q3 | 552.61 Million SEK | -13.98% |
2018 FY | 444.53 Million SEK | -7.36% |
2018 Q4 | 444.53 Million SEK | -19.56% |
2018 Q2 | 642.41 Million SEK | -13.07% |
2017 Q1 | 651.22 Million SEK | 1070.59% |
2017 Q4 | 479.82 Million SEK | -9.05% |
2017 Q3 | 527.59 Million SEK | -11.47% |
2017 Q2 | 595.96 Million SEK | -8.49% |
2017 FY | 479.82 Million SEK | 762.48% |
2016 Q4 | 55.63 Million SEK | 0.0% |
2016 FY | 55.63 Million SEK | 1163.8% |
2016 Q1 | - SEK | 0.0% |
2015 FY | 4.4 Million SEK | -66.46% |
2014 FY | 13.12 Million SEK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Alligator Bioscience AB (publ) | 118.45 Million SEK | -101.248% |
Ziccum AB (publ) | 14.97 Million SEK | -1492.159% |
Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1089.452% |
BioArctic AB (publ) | 1.18 Billion SEK | 79.902% |
Sprint Bioscience AB (publ) | 62.37 Million SEK | -282.157% |
Mendus AB (publ) | 755.95 Million SEK | 68.467% |
Genovis AB (publ.) | 288.85 Million SEK | 17.475% |
Intervacc AB (publ) | 259.61 Million SEK | 8.179% |
QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -468.121% |
Active Biotech AB (publ) | 44 Million SEK | -441.768% |
Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 14.482% |
Bio-Works Technologies AB (publ) | 62.15 Million SEK | -283.54% |
Aptahem AB (publ) | 63.02 Million SEK | -278.228% |
Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 51.964% |
Kancera AB (publ) | 65.64 Million SEK | -263.143% |
Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 32.151% |
Fluicell AB (publ) | 9.34 Million SEK | -2452.227% |
Saniona AB (publ) | 64.14 Million SEK | -271.635% |
Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -609.416% |
Biovica International AB (publ) | 131.4 Million SEK | -81.403% |
Spago Nanomedical AB (publ) | 52.98 Million SEK | -349.897% |
AcouSort AB (publ) | 34.51 Million SEK | -590.69% |
Xintela AB (publ) | 18.39 Million SEK | -1195.885% |
Abliva AB (publ) | 87.49 Million SEK | -172.435% |
Egetis Therapeutics AB (publ) | 760.2 Million SEK | 68.643% |
Karolinska Development AB (publ) | 1.25 Billion SEK | 81.057% |
OncoZenge AB (publ) | 20.34 Million SEK | -1071.967% |
Amniotics AB (publ) | 26.08 Million SEK | -813.816% |
2cureX AB (publ) | 16.62 Million SEK | -1333.853% |
CombiGene AB (publ) | 120.61 Million SEK | -97.64% |
Asarina Pharma AB (publ) | 6.07 Million SEK | -3822.626% |
Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 87.457% |
Camurus AB (publ) | 1.9 Billion SEK | 87.505% |
Corline Biomedical AB | 100.1 Million SEK | -138.128% |
IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -34.585% |
Isofol Medical AB (publ) | 140.59 Million SEK | -69.547% |
I-Tech AB | 152.44 Million SEK | -56.372% |
Hansa Biopharma AB (publ) | 1.01 Billion SEK | 76.585% |
Cyxone AB (publ) | 43.65 Million SEK | -446.05% |
ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -202.925% |
Biosergen AB | 7.2 Million SEK | -3210.346% |
Cantargia AB (publ) | 223.71 Million SEK | -6.556% |
NextCell Pharma AB | 81.28 Million SEK | -193.251% |
Xspray Pharma AB (publ) | 765.26 Million SEK | 68.85% |
Elicera Therapeutics AB (publ) | 30.17 Million SEK | -690.037% |
Nanologica AB (publ) | 77.42 Million SEK | -207.867% |
SynAct Pharma AB | 228.01 Million SEK | -4.543% |
Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -790.7% |
Stayble Therapeutics AB (publ) | 21.7 Million SEK | -998.371% |
LIDDS AB (publ) | 17.65 Million SEK | -1250.201% |
Lipum AB (publ) | 12.11 Million SEK | -1868.439% |
BioInvent International AB (publ) | 1.4 Billion SEK | 82.975% |
Alzinova AB (publ) | 123.18 Million SEK | -93.506% |
Pila Pharma AB (publ) | 8.45 Million SEK | -2719.373% |
Guard Therapeutics International AB (publ) | 85.22 Million SEK | -179.698% |
Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1503.188% |
Simris Alg AB (publ) | 174.55 Million SEK | -36.566% |
Diamyd Medical AB (publ) | 217.03 Million SEK | -9.832% |
Xbrane Biopharma AB (publ) | 653.5 Million SEK | 63.523% |
Ascelia Pharma AB (publ) | 87.07 Million SEK | -173.771% |
Diagonal Bio AB (publ) | 28.5 Million SEK | -736.179% |